Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
TREATMENT AND PREVENTION OF REACTIVE OXYGEN METABOLITE-MEDIATED CELLULAR DAMAGE
Document Type and Number:
WIPO Patent Application WO/2000/040241
Kind Code:
A2
Abstract:
The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.

Inventors:
HELLSTRAND KRISTOFFER
HERMODSSON SVANTE
GEHLSEN KURT R
Application Number:
PCT/US2000/000314
Publication Date:
July 13, 2000
Filing Date:
January 07, 2000
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
MAXIM PHARM INC (US)
International Classes:
A61K31/00; A61K31/015; A61K31/33; A61K31/355; A61K31/375; A61K31/4045; A61K31/417; A61K38/44; A61K45/06; A61P1/00; A61P9/10; A61P11/00; A61K45/00; A61P25/16; A61P25/28; A61P29/00; A61P31/00; A61P31/14; A61P37/00; A61P37/02; A61P39/00; A61P39/06; (IPC1-7): A61K31/417; A61K31/33; A61K31/4045; A61P11/00; A61P9/10; A61P31/14; A61P37/00; A61P29/00; A61P25/28; A61P25/16; A61P39/00; A61P39/06
Domestic Patent References:
WO1996005289A11996-02-22
WO1993024144A11993-12-09
WO1995003819A11995-02-09
Other References:
DATABASE WPI Derwent Publications Ltd., London, GB; AN 1988-336291 XP002135228 SIMONYAN M A ET AL: "Examination of gastric secretory function-involves using copper-zinc superoxidedismutase and histamine-di:hydrochloride as stimulator to increase information from method" & SU 1 394 134 A (TERN MED INST), 7 May 1988 (1988-05-07)
YONEKURA M ET AL: "Influence of ascorbic acid supplementation on the toxic effects of dietary histamine in chicks" JAPANESE POULTRY SCIENCE, vol. 24, 1987, pages 354-362, XP000885454
WATANABE S ET AL: "Stomach ulcer and lysosomal cathepsin" TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 134, 1981, pages 39-44, XP000882611
DEMLING R H: "The role of mediators in human ARDS" JOURNAL OF CRITICAL CARE, vol. 3, no. 1, 1988, pages 56-72, XP000882581
BONE R C: "The adult respiratory distress syndrome: treatment in the next decase" RESPIRATORY CARE, vol. 29, no. 3, March 1984 (1984-03), page 249-262 XP000882582
Attorney, Agent or Firm:
Hunt, Dale C. (Martens Olson & Bear, LLP, 16th floor, 620 Newport Center Driv, Newport Beach CA, US)
Download PDF:
View/Download PDF      PDF Help
Claims:
WHAT IS CLAIMED IS:
1. A method for inhibiting and reducing enzymatically produced ROMmediated oxidative damage in a subject comprising the step of: administering a compound effective to inhibit the production or release of enzymatically produced reactive oxygen metabolites to a subject suffering from a condition caused or exacerbated by enzymatically produced ROMmediated oxidative damage.
2. The method of Claim 1, wherein the reactive oxygen metabolites are released constitutively.
3. The method of Claim 1, wherein the reactive oxygen metabolites are released in response to a respiratory burst.
4. The method of Claim 1, wherein said condition is selected from the group consisting of ARDS, ischemia or reperfusion injury, infectious disease, autoimmune or inflammatory diseases, and neurodegenerative diseases.
5. The method of Claim 1, wherein the compound is selected from the group consisting of histamine, H2 receptor agonists, NADPH oxidase inhibitors, serotonin and serotonin agonists.
6. The method of Claim 5 further comprising the step of administering an effective amount of a ROM scavenger.
7. The method of Claim 6, wherein the step of administering said ROM scavenger results in ROM scavenger catalyzed decomposition of ROMs.
8. The method of Claim 6, wherein the scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, and vitamin C.
9. A method for treating a subject suffering from a disease state wherein phagocyte produced, ROM mediated oxidative damage can occur, comprising the steps of: identifying a subject with a condition in which enzymatically generated ROMs released in response to a respiratory burst produce ROMmeditated oxidative damage; and administering a compound effective to inhibit the production or release of ROMs.
10. The method of Claim 9, wherein said condition is selected from the group consisting of ARDS, ischemia or reperfusion injury, infectious disease, autoimmune or inflammatory diseases, and neurodegenerative diseases.
11. The method of Claim 10, wherein the step of administering said compound further comprises administering a compound selected from the group comprising histamine, H2 receptor agonists, serotonin, serotonin agonists, and NADPH oxidase inhibitors.
12. The method of Claim 11, further comprising administering an effective amount of a ROM scavenger.
13. The method of Claim 12, wherein the step of administering said ROM scavenger results in the reactive oxygen metabolites scavenger catalyzed decomposition of reactive oxygen metabolites.
14. The method of Claim 13, wherein the step of administering said reactive oxygen metabolites scavenger further comprises administering a compound selected from the group consisting of catalase, superoxide dismutase, glutathione peroxidase, and ascorbate peroxidase.
15. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier, a compound effective to inhibit the production or release of enzymatically generated ROMs and a compound effective to scavenge ROMs.
16. The pharmaceutical composition of Claim 15, wherein said compound effective to inhibit the <BR> <BR> <BR> <BR> production or release of ROMs is selected from the group consisting of histamine, H2 receptor agonists, serotonin, serotonin agonists, and NADPH oxidase inhibitors.
17. The pharmaceutical composition of Claim 15, wherein the compound effective to scavenge ROMs is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, and vitamin C.
18. Use of a compound effective to inhibit the production or release of enzymatically produced reactive oxygen metabolites in the manufacture of a medicament for treatment of a condition caused or exacerbated by enzymatically produced reactive oxygen metabolitemediated oxidative damage by administering said medicament to a subject suffering from said condition.
19. The use of Claim 18, wherein the reactive oxygen metabolites are released constitutively.
20. The use of Claim 18, wherein the reactive oxygen metabolites are released in response to a respiratory burst.
21. The use of Claim 18, wherein said condition is selected from the group consisting of ARDS, ischemia or reperfusion injury, infectious disease, autoimmune or inflammatory diseases, and neurodegenerative diseases.
22. The use of Claim 18, wherein the compound is selected from the group consisting of histamine, H2 receptor agonists, NADPH oxidase inhibitors, serotonin and serotonin agonists.
23. The use of Claim 22, wherein said medicament further comprises an effective amount of a reactive oxygen metabolite scavenger.
24. The use of Claim 23, wherein the scavenger is selected from the group consisting of catalase, glutathione peroxidase, ascorbate peroxidase, superoxide dismutase, glutathione peroxidase, ascorbate peroxidase, vitamin A, vitamin E, and vitamin C.
25. Use of a compound effective to inhibit the production or release of reactive oxygen metabolites in the manufacture of a pharmaceutical preparation for the treatment of a condition in which enzymatically generated reactive oxygen metabolites released in response to a respiratory burst produce reactive oxygen metabolitemeditated oxidative damage.
26. The use of Claim 25, wherein said condition is selected from the group consisting of ARDS, ischemia or reperfusion injury, infectious disease, autoimmune or inflammatory diseases, and neurodegenerative diseases.
27. The use of Claim 26, wherein said compound selected from the group comprising histamine, H2 receptor agonists, serotonin, serotonin agonists, and NADPH oxidase inhibitors.
28. The use of Claim 27, wherein said pharmaceutical preparation further comprising an effective amount of a reactive oxygen metabolite scavenger.
29. The use of Claim 28, wherein the step of administering said reactive oxygen metabolites scavenger is selected from the group consisting of catalase, superoxide dismutase, glutathione peroxidase, and ascorbate peroxidase.
Description:
INTERNATIONAL SEARCH REPORT | Inter onalApplicationNo PCT/US 00/00314 C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT Category ° Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. X YONEKURA M ET AL :"Influence of ascorbic 15-17 acid supplementation on the toxic effects of dietary histamine in chicks" JAPANESE POULTRY SCIENCE, vol. 24, 1987, pages 354-362, XP000885454 abstract X WATANABE S ET AL :"Stomach ulcer and 15-17 lysosomal cathepsin" TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 134, 1981, pages 39-44, XP000882611 abstract A WO 96 05289 A (SYNTELLO INC) 1-29 22 February 1996 (1996-02-22) page 3, line 1-page 3, line 13 ; claims 1, 2 A WO 93 24144 A (ESTERO ANSTALT ; HELLSTRAND 1-29 KRISTOFFER (SE) ; HERMODSSON SVANTE (SE)) 9 December 1993 (1993-12-09) claims 6, 9 A WO 95 03819 A (SCRIPPS RESEARCH INST) 1-29 9 February 1995 (1995-02-09) page 5, line 22-page 6, line 14 A DEMLING R H :"The role of mediators in 1-29 human ARDS" JOURNAL OF CRITICAL CARE, vol. 3, no. 1, 1988, pages 56-72, XP000882581 "Oxygen radicals"on page 61 and "Histamine"on page 63 A BONE R C :"The adult respiratory distress 1-29 syndrome : treatment in the next decase" RESPIRATORY CARE, vol. 29, no. 3, March 1984 (1984-03), page 249-262 XP000882582 table 2 summary 3 3 Inl., ational appilcation No. INTERNATIONAL SEARCH REPORT PCT/US 00/00314 Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) This International Search Report has not been established in respect of certain claims under Article 17 (2) (a) for the following reasons : 1 Claims Nos, because they relate to subject matter not required to be searched by this Authority, namely : 2. Claims Nos. : because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, speeifically : 3 Claims Nos. : because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6. 4 (a). Box 11 Observations where unity of invention is lacking (Continuation of item 2 of first sheet) This International Searching Authority found multiple inventions in this internationa ! application, as follows : See additional sheet 1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims. 2. nj As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee. 3. As on ! y some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos. : 4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims ; it is covered by claims Nos. : 1-29 in part Remark on Protest The additional search fees were accompanied by the applicant's protest. u El No protest accompanied the payment of additional search fees. FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 1. Claims: 1-29 in part methods/uses involving treatment of ARDS using a HISTAMIME OR AND H-2 RECEPTOR AGONIST and compositions comprising a HISTAMINE OR AND H-2 RECEPTOR AGONIST in combination with a compound effective to scavenge ROMS.

2. Claims : 1-29 in part methods/uses involving treatment of ARDS using an NADPH OXIDASE INHIBITOR and compositions comprising an NADPH OXIDASE INHIBITOR in combination with a compound effective to scavenge ROMS 3. Claims : 1-29 in part methods/uses involving treatment of ARDS using SEROTONIN OR A SEROTONIN AGONIST and compositions comprising a SEROTONIN OR A SEROTONIN AGONIST in combination with a compound effective to scavenge ROMS 4. Claims : 1-29 in part methods/uses involving treatment of ISCHAEMIA OR REPERFUSION INJURY using a HISTAMINE OR AND H-2 RECEPTOR AGONIST and compositions comprising a HISTAMINE OR AND H-2 RECEPTOR AGONIST in combination with a compound effective to scavenge ROMS.

5. Claims : 1-29 in part methods/uses involving treatment of ISCHAEMIA OR REPERFUSION INJURY using an NADPH OXIDASE INHIBITOR and compositions comprising an NADPH OXIDASE INHIBITOR in combination with a compound effective to scavenge ROMS.

6. Claims : 1-29 in part methods/uses involving treatment of ISCHAEMIA OR REPERFUSION INJURY using SEROTONIN OR A SEROTONIN AGONIST and compositions comprising a SEROTONIN OR A SEROTONIN AGONIST in combination with a compound effective to scavenge ROMS.

7. Claims : 1-29 in part methods/uses involving treatment of INFECTIOUS DISEASES using a HISTAMINE OR AND H-2 RECEPTOR AGONIST and compositions comprising a HISTAMINE OR AND H-2 RECEPTOR AGONIST in combination with a compound effective to scavenge FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 ROMS.

8. Claims : 1-29 in part methods/uses involving treatment of INFECTIOUS DISEASES using an NADPH OXIDASE INHIBITOR and compositions comprising an NADPH OXIDASE INHIBITOR in combination with a compound effective to scavenge ROMS 9. Claims : 1-29 in part methods/uses involving treatment of INFECTIOUS DISEASES using SEROTONIN OR A SEROTONIN AGONIST and compositions comprising a SEROTONIN OR A SEROTONIN AGONIST in combination with a compound effective to scavenge ROMS 10. Claims : 1-29 in part methods/uses involving treatment of AUTOIMMUNE DISEASES using a HISTAMINE OR AND H-2 RECEPTOR AGONIST and compositions comprising a HISTAMINE OR AND H-2 RECEPTOR AGONIST in combination with a compound effective to scavenge ROMS.

11. Claims : 1-29 in part methods/uses involving treatment of AUTOIMMUNE DISEASES using an NADPH OXIDASE INHIBITOR and compositions comprising an NADPH OXIDASE INHIBITOR in combination with a compound effective to scavenge ROMS 12. Claims : 1-29 in part methods/uses involving treatment of AUTOIMMUNE DISEASES using SEROTONIN OR A SEROTONIN AGONIST and compositions comprising a SEROTONIN OR A SEROTONIN AGONIST in combination with a compound effective to scavenge ROMS 13. Claims : 1-29 in part methods/uses involving treatment of INFLAMMATORY DISEASES using a HISTAMINE OR AND H-2 RECEPTOR AGONIST and compositions comprising a HISTAMINE OR AND H-2 RECEPTOR AGONIST in combination with a compound effective to scavenge ROMS.

14. Claims: 1-29 in part FURTHER INFORMATION CONTINUED FROM PCTIISA/210 methods/uses involving treatment of INFLAMMATORY DISEASES using an NADPH OXIDASE INHIBITOR and compositions comprising an NADPH OXIDASE INHIBITOR in combination with a compound effective to scavenge ROMS 15. Claims : 1-29 in part methods/uses involving treatment of INFLAMMATORY DISEASES using SEROTONIN OR A SEROTONIN AGONIST and compositions comprising a SEROTONIN OR A SEROTONIN AGONIST in combination with a compound effective to scavenge ROMS.

16. Claims : 1-29 in part methods/uses involving treatment of NEURODEGENERATIVE DISEASES using a HISTAMINE OR AND H-2 RECEPTOR AGONIST and compositions comprising a HISTAMINE OR AND H-2 RECEPTOR AGONIST in combination with a compound effective to scavenge ROMS.

17. Claims : 1-29 in part methods/uses involving treatment of NEURODEGENERATIVE DISEASES using an NADPH OXIDASE INHIBITOR and compositions comprising an NADPH OXIDASE INHIBITOR in combination with a compound effective to scavenge ROMS 18. Claims : 1-29 in part methods/uses involving treatment of NEURODEGENERATIVE DISEASES using SEROTONIN OR A SEROTONIN AGONIST and compositions comprising a SEROTONIN OR A SEROTONIN AGONIST in combination with a compound effective to scavenge ROMS INTERNATIONAL SEARCH REPORT pterr nal Application No nterr na) Apphcation No ..., ormation on patent family members PCT/US 00/00314 Patent document Publication Patent family Publication : ! ted in search report date member (s) date SU 1394134 A 07-05-1988 NONE wu 9605289 A 22-02-1996 AU 709635 B 02-09-1999 AU 3202795 A 07-03-1996 CA 2196756 A 22-02-1996 EP 3775197 A 28-05-1997 JP 10504304 T 28-04-1998 us 6071509 A 06-06-2000 US 6063373 A 16-05-2000 WO 9324144 A 09-12-1993 AT 192338 T 15-05-2003 AU 672610 B 10-10-1996 AU 4366093 A 30-12-1993 CA 2136952 A 09-12-1993 DE 69328558 D 08-06-2000 EP 0652768 A 17-05-1995 JP 2888259 B 10-05-1999 JP 8502024 T 05-03-1996 SE 9201719 A 04-12-1993 US 5728378 A 17-03-1998 WO 9503819 A 09-02-1995 US 5726155 A 10-03-1998 AU 7409294 A 28-02-1995 ! I I




 
Previous Patent: METHODS AND COMPOSITIONS FOR TOPICAL TREATMENT OF DAMAGED TISSUE USING REACTIVE OXYGEN METABOLITE PR...

Next Patent: PREPARATION OF A COMPOSITION AGAINST HEPATITIS B-, HI-, PARAMYXO- AND ORTHOMYXOVIRUSES